ArticleBiosensors & bioelectronics2025
Nanomechanical systems for the rapid detection of HIV-1 p24 antigen.
Article in Biosensors & bioelectronics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Recent Advances in Graphene-Based Field-Effect Transistor Biosensors for Disease Biomarker Detection and Clinical Prospects.Biosensors · 2026Review
- Immunomodulatory biomaterials in HIV-1 infection prevention, control and treatment.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Early detection of HIV is crucial for reducing transmission and ensuring timely initiation of antiretroviral therapy (ART), significantly improving patient outcomes. Although diagnostic tests have advanced from first-generation antibody detection assays to fourth-generation immunoassays that detect both HIV antibodies and the p24 antigen, these are limited to clinical labs. Their longer processing times, high costs, and the requirement for multiple patient visits highlight the need for rapid, affordable point-of-care (POC) diagnostics. This study introduces a nanomechanical cantilever-based biosensor for the rapid detection of HIV-1 p24 antigen, a key marker for early diagnosis. The platform demonstrated remarkable sensitivity, detecting p24 at concentrations as low as 100 fg/mL in solution and 1 pg/mL in human serum, and was quantitative within several orders of magnitude. After functionalizing the microcantilevers with two broadly cross-reactive monoclonal antibodies (ANT-152 and C65690M), the system was able to detect p24 from a wide range of HIV-1 subtypes. Furthermore, this biosensor was found to be compatible with various blood processing methods and with a direct electronic output. This platform's high sensitivity, specificity, and applicability across multiple HIV subtypes underscores its potential for future development into a next-generation POC diagnostic tool.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.